8-K - Karyopharm Therapeutics Inc. (0001503802) (Filer)
Published . Updated .
Key takeaways
- 8-K - Karyopharm Therapeutics filed an 8-K with the SEC on Nov 5 (a notice of a material company event).
- Exposed: KPTI
- Market reaction: KPTI −37.7% by the next session
Market Call
Think this story will push the stock up or down over the next three trading days? Make a free call and see what other readers think. Points are play money with no cash value.
Get these market calls by email
The week's biggest market-moving stories, Congress trades and Trump posts, with the tickers they touch. Free, one email a week.
Free. We only use your email to send the digest, never sell or share it, and every email has a one-click unsubscribe link. See our privacy policy.
8-K - Karyopharm Therapeutics filed an 8-K with the SEC on Nov 5 (a notice of a material company event).
Directly affected
- KPTI Karyopharm Therapeutics-90.5% 30d
Named in this report.
Indirectly affected
- XLV Health Care Select Sector SPDR
Health Care Select Sector SPDR holds the health sector that Karyopharm Therapeutics belongs to, so it often moves with news about it.
- LLY Eli Lilly and+15.5% 30d
Eli Lilly and is a peer of Karyopharm Therapeutics in pharmaceutical preparations; rivals often move on the same news.
- JNJ Johnson & Johnson+0.1% 30d
Johnson & Johnson is a peer of Karyopharm Therapeutics in pharmaceutical preparations; rivals often move on the same news.
- ABBV AbbVie+9.0% 30d
AbbVie is a peer of Karyopharm Therapeutics in pharmaceutical preparations; rivals often move on the same news.
- MRK Merck+3.5% 30d
Merck is a peer of Karyopharm Therapeutics in pharmaceutical preparations; rivals often move on the same news.
- ABT Abbott Laboratories+10.3% 30d
Abbott Laboratories is a peer of Karyopharm Therapeutics in pharmaceutical preparations; rivals often move on the same news.
Price reaction, T-5 to T+3
| Ticker | T-5 | T-3 | T-1 | T0 | T+1 | T+2 | T+3 |
|---|---|---|---|---|---|---|---|
| KPTI | +949.64% | +34.70% | base | -25.78% | -37.71% | after close | after close |
| XLV | -2.96% | -2.66% | base | -2.36% | -2.53% | after close | after close |
| LLY | -3.15% | -0.45% | base | -3.07% | -4.46% | after close | after close |
| JNJ | -0.43% | -2.09% | base | -1.43% | -0.00% | after close | after close |
| ABBV | -1.41% | -2.06% | base | -1.94% | -1.14% | after close | after close |
| MRK | -2.69% | -1.28% | base | -2.02% | -2.40% | after close | after close |
| ABT | -9.53% | -4.57% | base | -1.75% | -4.84% | after close | after close |
Closing-price change versus T-1, the last close before the story. T0 to T+3 fill in after each market close. Prices: Alpaca IEX.
Filed: 2026-11-05 AccNo: 0001193125-26-448516 Size: 147 KB Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Source: sec-edgar
Karyopharm Therapeutics (KPTI)
In the last 4 similar stories, Karyopharm Therapeutics (KPTI) moved an average of -35.37% the next day. The best was -11.83% and the worst was -85.85%, from 4 prices.
| Company | When | Average | Largest gain | Largest drop | Prices |
|---|---|---|---|---|---|
| Karyopharm Therapeutics (KPTI) | the next day | -35.37% | -11.83% | -85.85% | 4 |
| Karyopharm Therapeutics (KPTI) | three days later | -27.67% | +52.35% | -90.40% | 4 |
Karyopharm Therapeutics (KPTI) since this story, compared with the market
| Company | When | Move | Status |
|---|---|---|---|
| ABBV | that day | -1.94% | final price |
| ABBV | the next day | -1.14% | final price |
| ABBV | three days earlier | -2.06% | final price |
| ABBV | five days earlier | -1.41% | final price |
| ABT | that day | -1.75% | final price |
| ABT | the next day | -4.84% | final price |
| ABT | three days earlier | -4.57% | final price |
| ABT | five days earlier | -9.53% | final price |
| JNJ | that day | -1.43% | final price |
| JNJ | the next day | -0.00% | final price |
| JNJ | three days earlier | -2.09% | final price |
| JNJ | five days earlier | -0.43% | final price |
| Karyopharm Therapeutics (KPTI) | that day | -25.78% | final price |
| Karyopharm Therapeutics (KPTI) | the next day | -37.71% | final price |
| Karyopharm Therapeutics (KPTI) | three days earlier | +34.70% | final price |
| Karyopharm Therapeutics (KPTI) | five days earlier | +949.64% | final price |
| LLY | that day | -3.07% | final price |
| LLY | the next day | -4.46% | final price |
| LLY | three days earlier | -0.45% | final price |
| LLY | five days earlier | -3.15% | final price |
| MRK | that day | -2.02% | final price |
| MRK | the next day | -2.40% | final price |
| MRK | three days earlier | -1.28% | final price |
| MRK | five days earlier | -2.69% | final price |
| XLV | that day | -2.36% | final price |
| XLV | the next day | -2.53% | final price |
| XLV | three days earlier | -2.66% | final price |
| XLV | five days earlier | -2.96% | final price |
Congressional trades in the stocks in this story
- Rep. Rohit Khanna bought Eli Lilly (LLY) (held by a spouse), worth $1,001 - $15,000 on 4 Sep 2026. That is 62 days before publication. Filed 7 Oct 2026. View the filing.
- Rep. Thomas H. Kean Jr sold Johnson & Johnson (JNJ), worth $1,001 - $15,000 on 30 Sep 2026. That is 36 days before publication. Filed 30 Oct 2026. View the filing.
- Rep. Rohit Khanna bought Johnson & Johnson (JNJ) (held by a spouse), worth $1,001 - $15,000 on 25 Sep 2026. That is 41 days before publication. Filed 7 Oct 2026. View the filing.
- Rep. Lloyd Doggett bought Johnson & Johnson (JNJ), worth $1,001 - $15,000 on 8 Sep 2026. That is 58 days before publication. Filed 5 Oct 2026. View the filing.
- Rep. Pete Sessions sold AbbVie (ABBV), worth $15,001 - $50,000 on 14 Sep 2026. That is 52 days before publication. Filed 18 Sep 2026. View the filing.
- Rep. Rohit Khanna sold AbbVie (ABBV) (held by a spouse), worth $1,001 - $15,000 on 4 Sep 2026. That is 62 days before publication. Filed 7 Oct 2026. View the filing.
- Rep. Maria Elvira Salazar sold Merck (MRK), worth $1,001 - $15,000 on 24 Sep 2026. That is 42 days before publication. Filed 7 Oct 2026. View the filing.
- Rep. Maria Elvira Salazar bought Merck (MRK), worth $15,001 - $50,000 on 19 Aug 2026. That is 78 days before publication. Filed 9 Sep 2026. View the filing.
- Rep. Pete Sessions sold Abbott Laboratories (ABT) (held by a spouse), worth $50,001 - $100,000 on 2 Oct 2026. That is 34 days before publication. Filed 27 Oct 2026. View the filing.
- Rep. Gilbert Cisneros bought Abbott Laboratories (ABT), worth $1,001 - $15,000 on 18 Sep 2026. That is 48 days before publication. Filed 12 Oct 2026. View the filing.
- Rep. Thomas H. Kean Jr sold Abbott Laboratories (ABT), worth $1,001 - $15,000 on 17 Sep 2026. That is 49 days before publication. Filed 30 Oct 2026. View the filing.
Public disclosure filings, not a recommendation. The filing link is the source document. News use of these reports still sits under 5 U.S.C. § 13107(c).
Who gains and who loses around Karyopharm Therapeutics (KPTI)
Companies carried with this story
- KPTI Karyopharm Therapeutics
In “8-K - Karyopharm Therapeutics Inc. (0001503802) (Filer),” Karyopharm Therapeutics (KPTI) is linked, with no stored direction, high confidence. Reason on file: SEC 8-K filing -> direct issuer disclosure -> KPTI
How “8-K - Karyopharm Therapeutics Inc. (0001503802) (Filer)” reaches Karyopharm Therapeutics (KPTI)
“8-K - Karyopharm Therapeutics Inc. (0001503802) (Filer)” (5 Nov 2026) reaches Karyopharm Therapeutics (KPTI) through this story.
What ties Karyopharm Therapeutics (KPTI) to the headline is this: SEC 8-K filing -> direct issuer disclosure -> KPTI
The price range for Karyopharm Therapeutics (KPTI), and the dates in the story
KPTI traded between 0.05 and 0.94 across 20 sessions. The latest close on file is 0.06.
How solid “8-K - Karyopharm Therapeutics Inc. (0001503802) (Filer)” looks
14 out of 100
“8-K - Karyopharm Therapeutics Inc. (0001503802) (Filer)” scores 14 out of 100. The score uses 1 sources, and 1 linked companies.